Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Amyotrophic Lateral Sclerosis (ALS)
2019-004619-30Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Change from baseline in ALSFRS-R total score. Started Feb 2020; status: completed.
02
Drugs
ravulizumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2019-004619-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004619-30.